Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Igor Puzanov

7 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Other

VICCMEL14103

08/17/2015

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec

Treatment

VICCURO1514

08/06/2015

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 ANTIBODY) in Combination with BEVACIZUMAB versus SUNITINIB in Patients with Untreated Advanced Renal Cell Carcinoma.

Treatment

VICCMEL14112

07/29/2015

A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy CheckMate 204: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 204

Treatment

VICCMEL1471

02/04/2015

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

Treatment

VICCPHI13113

01/22/2015

A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors.

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers